$CRNX 0.55 Developing
- Date
- Jul 6, 2026
- Mentions
- 1
- Unique authors
- 1
- Sector
- biotech
- Stance
- neutral
- On card
- no
Sentiment history
bullish
neutral
mixed
bearish
line = signal
dashed = price
No sentiment history available for $CRNX yet.
Sentiment
neutral 1
Notable posts
-
neutral 41 eng
Vertex Pharmaceuticals $VRTX agreed to buy Crinetics Pharmaceuticals $CRNX for $10B cash, expanding into endocrinology. Deal price: $85/share, a 102% premium to Crinetics’ prior close. Crinetics’ lead drug, Palsonify, targets acromegaly, with another program in congenital adrenal hyperplasia. Vertex says the assets could generate over $5B in peak annual revenue. Deal expected to close in Q3.
view on X →
Only one day of history so far — the signal arc fills in as the daily job runs.